Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03896230 · ClinicalTrials.gov registry record · Phase 4
Ketamine for Pain in the Emergency Department
A Phase 4 study, sponsored by Hackensack Meridian Health.
- Terminated
- Registry status
- Phase 4
- Development phase
- 11
- Enrollment target
NCT03896230 is a Phase 4 study that was terminated before completion, run by Hackensack Meridian Health. The registered enrollment target is 11 participants.
The verdict
NCT03896230, a Phase 4 study, was terminated before completion, sponsored by Hackensack Meridian Health.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 11 participants
- Enrollment target
Study Summary
This study will prospectively compare the mean Numerical Rating Scale (NRS) pain score reduction amongst three recommended dosing strategies of intravenous ketamine (0.1 mg/kg, 0.2 mg/kg, and 0.3mg/kg) for acute pain in the emergency department (ED).This study will also examine the frequency of adverse events secondary to ketamine including fatigue, dizziness, nausea, headache, feeling of unreality, changes in hearing or vision, mood changes, generalized discomfort, and hallucinations, changes in vital signs. Subgroups for exploratory analysis based on the need for rescue analgesia within two hours of ketamine administration, adequate pain relief, previous opioid tolerance, and age (adults \< 65 years old and \> 65 years old).
Interventions
- DRUG Ketamine Injectable Product
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2019-05-03 |
| Est. Completion | 2019-12-20 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03896230
The ClinicalTrials.gov registry entry for NCT03896230 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hackensack Meridian Health, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ketamine Injectable Product is the first listed.
NCT03896230 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03896230 about?
NCT03896230 is a clinical study titled "Ketamine for Pain in the Emergency Department". This study will prospectively compare the mean Numerical Rating Scale (NRS) pain score reduction amongst three recommended dosing strategies of intravenous ketamine (0.1 mg/kg, 0.2 mg/kg, and 0.3mg/kg) for acute pain in the emergency department (ED).This study will also examine the frequency of adve...
What is the current status of trial NCT03896230?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 11 participants. The study started on 2019-05-03. Estimated completion is 2019-12-20.
What interventions are being tested in trial NCT03896230?
The interventions under investigation include: Ketamine Injectable Product (DRUG).
Who is sponsoring clinical trial NCT03896230?
This trial is sponsored by Hackensack Meridian Health, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.